mesenchym
stromal
cell
msc
cellular
therapi
european
union
classifi
advanc
therapi
medicin
product
atmp
product
must
fulfil
requir
good
manufactur
practic
gmp
rule
despit
classif
medicin
product
alreadi
well
recogn
still
lack
inform
indic
valid
method
adapt
noncompendi
compendi
method
peculiar
biolog
product
intrins
characterist
differenti
classic
synthet
biolog
drug
present
paper
present
result
valid
studi
perform
context
msc
develop
atmp
clinic
experiment
use
specif
describ
valid
polici
follow
steril
test
endotoxin
adventiti
virus
cell
count
immunophenotyp
work
demonstr
possibl
fulli
valid
analyt
method
also
atmp
riskbas
approach
fill
gap
prescript
avail
guidelin
shape
tradit
medicin
product
peculiar
characterist
novel
extrem
promis
new
drug
manufactur
pharmaceut
biopharmaceut
product
subject
standard
qualiti
system
regul
good
manufactur
practic
gmp
rule
mesenchym
stromal
cell
msc
repres
cell
therapi
product
european
union
regul
classifi
advanc
therapi
medicin
product
atmp
consequ
product
must
take
place
accord
gmp
standard
qualiti
control
depart
medicin
product
manufactur
plant
aim
guarante
qualiti
product
reli
evid
clear
relationship
accur
measur
critic
qualiti
attribut
product
safeti
ident
puriti
potenc
issu
well
describ
specif
guidelin
european
medicin
agenc
ema
safeti
deriv
demonstr
product
contain
adventiti
agent
bacteria
fungi
virus
well
compon
might
repres
hazard
patient
receiv
ident
cellular
compon
ensur
presenc
activ
substanc
may
consist
phenotyp
andor
genotyp
profil
definit
puriti
demonstr
cell
therapi
product
contain
high
concentr
activ
substanc
free
unwant
cell
popul
far
concern
desir
therapeut
effect
lastli
potenc
assay
measur
requir
biolog
activ
final
cell
product
relationship
mechan
action
gener
defin
clinic
purpos
valid
mean
context
success
demonstr
manufactur
qualiti
consist
action
provid
process
procedur
method
activ
actual
consist
fulfil
specif
requir
particular
accord
intern
confer
harmon
ich
guidelin
valid
analyt
method
requir
purpos
demonstr
procedur
test
adopt
qualiti
control
laboratori
suitabl
intend
use
appropri
give
result
term
qualiti
attribut
describ
valid
activ
gener
compos
four
step
qualif
personnel
equip
use
prerequisit
oper
descript
valid
strategi
written
approv
valid
protocol
perform
valid
experi
collect
result
consider
valid
report
valid
protocol
clearli
defin
role
respons
person
element
involv
valid
perform
equip
suppli
reagent
refer
materi
standard
valid
paramet
accept
criteria
guarante
fulfil
valid
specif
ich
guidelin
defin
follow
paramet
consid
valid
accuraci
precis
repeat
intermedi
precis
specif
detect
limit
quantit
limit
linear
rang
strategi
accept
criteria
method
detect
microbi
contamin
pharmaceut
product
microbiolog
examin
bacteri
endotoxin
mycoplasma
describ
european
pharmacopoeia
ph
eur
aim
valid
determin
specif
product
contain
substanc
may
interfer
result
analysi
sinc
atmp
natur
inert
product
appropri
consider
adapt
strategi
requir
regard
clinic
applic
design
accur
valid
studi
much
challeng
atmp
qualiti
control
depart
valid
noncompendi
analyt
method
method
includ
describ
offici
ph
eur
especi
term
ident
puriti
potenc
addit
limit
avail
appropri
standard
refer
materi
lack
specif
monograph
guidelin
make
valid
work
even
difficult
field
despit
import
issu
gmp
product
atmp
literatur
paper
regard
specif
valid
strategi
differ
approach
import
notic
recent
specif
gmp
guidelin
atmp
publish
first
time
distinct
investig
atmp
least
earli
experiment
clinic
phase
author
atmp
product
reach
market
author
state
concern
first
class
product
document
clearli
declar
full
valid
analyt
procedur
requir
demonstr
method
suitabl
may
suffici
wherea
valid
expect
clinic
atmp
advanc
experiment
phase
experi
risk
assess
alway
drive
atmp
develop
choic
base
approach
chose
valid
method
whose
result
use
releas
investig
atmp
inde
convinc
accur
specif
precis
method
possibl
confid
result
support
knowledg
cellular
product
way
toward
author
aim
paper
give
clear
explan
design
valid
compendi
noncompendi
method
determin
safeti
microbiolog
determin
bacteri
endotoxin
adventiti
virus
ident
puriti
cell
count
immunophenotyp
qualiti
control
gmp
msc
request
releas
criteria
earlyphas
clinic
trial
prerequir
valid
instrument
suppli
reagent
personnel
qualif
accord
gmp
guidelin
valid
instrument
suppli
reagent
perform
alreadi
describ
briefli
instrument
subject
instal
qualif
iq
accord
manufactur
specif
oper
qualif
oq
reagent
upon
receipt
properli
check
specif
record
author
gmp
staff
qualiti
control
depart
follow
continu
train
program
duti
personnel
involv
qualiti
control
procedur
qualiti
control
manag
respons
clearli
describ
written
analyt
protocol
job
descript
request
gmp
guidelin
method
valid
strategi
describ
detail
valid
protocol
report
chosen
ich
paramet
type
analysi
number
run
replic
formula
use
calcul
accept
criteria
instrument
oper
involv
time
schedul
complet
valid
studi
result
analysi
record
report
approv
respons
qualiti
control
rqc
depart
valid
criteria
met
rqc
manag
condit
noncompli
identifi
correct
caus
failur
reschedul
valid
activ
issu
new
plan
follow
paramet
use
valid
studi
herein
describ
specif
abil
assess
unequivoc
analyt
presenc
compon
may
expect
present
typic
might
includ
impur
ii
accuraci
close
agreement
valu
accept
either
convent
true
valu
accept
refer
valu
valu
found
noncompendi
valid
analysi
accuraci
express
follow
accuraci
error
e
calcul
accord
follow
formula
accuraci
percentag
valu
calcul
accord
follow
formula
iii
precis
close
agreement
degre
scatter
seri
measur
obtain
multipl
sampl
homogen
sampl
prescrib
condit
precis
consid
two
level
repeat
intraassay
precis
intermedi
precis
interassay
precis
calcul
consid
percentag
coeffici
variat
cv
seri
measur
calcul
formula
cv
standard
deviat
mean
iv
detect
limit
limit
detect
lod
lowest
amount
analyt
sampl
detect
necessarili
quantit
exact
valu
v
linear
abil
within
given
rang
obtain
test
result
directli
proport
concentr
amount
analyt
sampl
calcul
consid
correl
coeffici
r
squar
r
vi
rang
interv
upper
lower
concentr
amount
analyt
sampl
includ
concentr
demonstr
analyt
procedur
suitabl
level
precis
accuraci
linear
sourc
manufactur
accord
annex
gmp
guidelin
valid
method
perform
refer
retent
sampl
final
product
repres
msc
cord
blood
cb
bone
marrow
bm
briefli
start
materi
cb
bm
qualiti
control
analysi
introduc
class
bgmp
facil
seed
alpha
modifi
eagl
medium
macopharma
mouvaux
franc
supplement
respect
gammairradi
foetal
bovin
serum
fb
australian
origin
gibco
life
technolog
carlsbad
ca
usa
platelet
lysat
institut
klinisch
transfusionsmedizin
und
immungenetik
ulm
gmbh
ulm
german
concentr
total
nucleat
cell
tnc
cm
cultur
chamber
system
corn
lowel
hour
nonadher
cell
remov
wash
phosphatebuff
salin
pb
macopharma
complet
medium
chang
cultur
daili
monitor
coloni
appear
cultur
medium
chang
everi
three
day
confluenc
cell
detach
use
mllayer
trypleselect
version
use
moment
valid
lyophil
bacteri
strain
yeast
fungu
appropri
prepar
isol
casein
soybean
digest
agar
caso
agar
sabouraud
rightagar
sda
plate
merck
millipor
usa
incub
optimum
growth
condit
strain
store
use
recultiv
agar
plate
specif
condit
measur
quantiti
absorb
cell
suspens
dilut
obtain
two
concentr
one
cfuml
one
cfuml
batch
cultur
medium
test
steril
fertil
use
accord
ph
consid
quantiti
result
shown
report
extern
qualiti
program
valid
perform
three
batch
cbmsc
three
batch
bmmsc
purpos
verifi
compon
matrix
final
product
resuspend
antibacteri
activ
may
therefor
interfer
result
test
matrix
solut
cbmsc
cryopreserv
product
made
normal
salin
hsa
dmso
concentr
describ
bmmsc
fresh
product
resuspend
hsa
normal
salin
vol
vol
valid
scheme
evalu
paramet
display
tabl
analysi
carri
direct
inocul
microbi
cultur
medium
class
agmp
laminar
flow
hood
class
bgmp
surround
continu
particl
count
monitor
environment
oper
microbiolog
control
perform
accordingli
ph
eur
minimum
volum
test
maximum
volum
batch
cbmsc
ml
maximum
volum
batch
ml
ml
bmmsc
maximum
volum
batch
ml
therefor
order
suitabl
sampl
perform
steril
test
final
product
cell
suspens
divid
steril
tube
ml
tube
tube
inoculum
microorgan
ad
two
concentr
cfuml
cfuml
respect
way
microbi
strain
two
level
contamin
obtain
cfu
cfu
prepar
sampl
microorgan
autom
portabl
spectrophotometr
micropl
reader
equip
thermostat
control
incub
chamber
limulu
amebocyt
lysat
lal
cse
substrat
posit
control
place
within
prepackag
cartridg
could
directli
read
instrument
wavelength
nm
optim
detect
signal
gener
substrat
chromogen
lal
maximum
sensit
method
euml
valid
carri
cbmsc
studi
product
repres
worst
case
term
endotoxin
limit
respect
presenc
constitu
matrix
resuspend
describ
microbiolog
examin
valid
valid
protocol
briefli
summar
tabl
consist
essenti
three
phase
assur
standard
curv
criteria
cse
contain
cartridg
test
perform
supplier
batch
cartridg
provid
certif
analysi
contain
result
standard
curv
test
accord
ph
eur
standard
curv
perform
batch
cse
three
endotoxin
concentr
within
specifi
rang
three
replic
concentr
linear
standard
curv
given
absolut
valu
r
must
studi
product
calcul
endotoxin
limit
el
maximum
dilut
valid
mdv
accord
ph
eur
el
euml
calcul
formula
km
k
threshold
pyrogen
dose
endotoxin
per
kilogram
bodi
mass
intraven
administr
eukg
maximum
recommend
dose
product
per
kilogram
bodi
mass
mvd
valu
calcul
use
formula
el
c
correspond
concentr
test
solut
sinc
deal
cell
suspens
chemic
solut
impract
measur
concentr
product
mass
biolog
activ
volum
therefor
valu
c
fix
thu
impli
volum
unit
test
solut
correspond
one
unit
product
preliminari
test
interf
factor
step
perform
variou
dilut
product
accord
mvd
order
find
best
dilut
activ
andor
inhibit
enzymat
reaction
cellular
product
dilut
water
lal
minimum
volum
dispos
cartridg
contain
four
channelstwo
channel
cse
lal
serv
posit
control
channel
two
channel
lal
dilut
test
sampl
charg
four
well
cartridg
neg
control
repres
lal
reagent
water
charl
river
least
two
replic
instrument
gave
report
follow
result
indic
onset
time
time
necessari
achiev
detect
level
predetermin
absorb
coeffici
variat
cv
two
replic
posit
control
sampl
spike
recoveri
allow
check
interfer
inhibit
stimul
determin
alter
endotoxin
recoveri
order
valid
result
onset
time
neg
control
spike
sampl
must
greater
onset
time
percentag
cv
must
recoveri
spike
rate
directli
calcul
instrument
measur
accuraci
must
test
interf
factor
use
chosen
dilut
three
batch
product
confirm
preliminari
test
qualit
approach
base
realtim
onestep
rtpcr
assay
design
detect
respiratori
virus
nasopharyng
aspir
nasopharyng
swab
bronchoalveolar
lavag
chosen
summar
tabl
first
phase
valid
aim
defin
number
cell
need
optim
dnarna
extract
amplif
also
consid
possibl
inhibit
effect
dmso
genom
dna
obvious
present
sampl
three
batch
refer
cryopreserv
cbmsc
thaw
count
prepar
three
differ
cell
dose
cell
pellet
resuspend
lysi
buffer
atl
qiagen
hilden
germani
dna
rna
extract
use
automat
extractor
qiagen
final
volum
mgb
kit
pcr
mix
ad
volum
genom
extract
neg
control
extract
sampl
two
amplif
reaction
carri
thermocycl
realtim
pcr
system
appli
biosystem
foster
citi
ca
usa
first
one
aim
detect
miea
gene
exon
cmv
gene
encod
protein
ebv
second
one
direct
human
beta
globin
gene
verifi
extract
amplif
success
carri
without
inhibit
viral
titl
determin
standard
curv
set
use
four
scalar
concentr
plasmid
dna
copi
two
virus
accord
kit
instruct
standard
curv
r
accept
respiratori
virus
amplif
done
ad
extract
differ
master
mix
accord
manufactur
instruct
kit
contain
two
differ
control
first
one
pcr
control
pcrc
allow
verifi
amplif
carri
correctli
without
inhibit
substanc
contain
sampl
second
one
whole
process
control
wpc
target
rnase
allow
verifi
whole
process
extract
amplif
happen
correctli
without
inhibit
order
assess
specif
test
msc
cell
bmmsc
cbmsc
inocul
two
viral
load
known
posit
standard
accord
result
extern
qualiti
program
report
sinc
possibl
use
fifteen
respiratori
virus
inocul
cell
decid
use
posit
standard
repres
dna
viru
adenoviru
rna
viru
enteroviru
viral
quantiti
use
spike
cell
compar
low
high
viral
load
posit
patient
sampl
copi
cmv
copi
ebv
copi
adenoviru
adv
copi
enteroviru
hev
sampl
spike
hev
perform
without
proteinas
k
treatment
exclud
inhibit
rna
extract
due
treatment
need
proteinas
k
assess
sensibl
accuraci
precis
three
differ
batch
cbmsc
charg
viral
load
tenfold
sensit
cutoff
declar
manufactur
copi
adv
hev
respect
copi
cmv
ebv
respect
recoveri
calcul
genom
equival
geq
copi
sampl
possibl
appli
formula
indic
datasheet
built
plasma
sampl
result
express
quantiti
cmv
ebv
target
dna
gequreact
present
sampl
reaction
posit
control
consist
viral
nucleic
acid
alon
quantiti
paramet
calcul
compar
ct
valu
sampl
standard
curv
respiratori
virus
kit
qualit
possibl
demonstr
quantit
recoveri
two
neg
control
perform
neg
control
extract
process
water
extract
condit
neg
control
amplif
put
water
mix
amplif
precis
assess
within
technic
replic
within
three
batch
cbmsc
protocol
design
valid
autom
method
msc
count
system
chemometec
allerod
denmark
term
accuraci
precis
linear
comparison
manual
cell
count
method
hemocytomet
burker
chamber
nucleocount
portabl
devic
base
integr
fluoresc
microscop
principl
allow
count
total
viabl
cell
stain
propidium
iodid
pi
immobil
insid
charger
nucleocassett
refer
sampl
msc
three
batch
cbmsc
three
batch
bmmsc
resuspend
volum
ml
pb
order
test
differ
concentr
cell
shown
figur
cell
suspens
two
differ
sampl
count
duplic
total
dead
cell
first
cell
pretreat
buffer
lysi
chemometec
order
allow
pi
stain
cell
suspens
cell
stock
solut
serial
dilut
count
two
method
count
burker
chamber
perform
two
qualifi
oper
cell
suspens
load
five
field
count
follow
paramet
accept
criteria
set
accuraci
calcul
accuraci
error
hemocytomet
count
measur
valu
nucleocount
total
vital
count
accept
criteria
fix
e
e
linear
method
dilut
serial
count
calcul
r
precis
estim
repeat
intraassay
intermedi
precis
interassay
cv
less
immunophenotyp
valid
valid
design
immunophenotyp
analysi
figur
preced
preliminari
phase
consist
first
titrat
antibodi
use
instrument
set
includ
fluoresc
voltag
compens
setup
valid
phase
consist
evalu
paramet
complianc
ich
use
cytomet
fac
canto
ii
becton
dickinson
bd
bioscienc
san
jose
ca
usa
whose
reproduc
setup
check
cs
bead
bd
acquisit
accord
manufactur
instruct
refer
sampl
three
batch
msc
n
cbmsc
n
bmmsc
cell
use
posit
neg
standard
stmsc
respect
myeloid
cell
line
posit
hematopoiet
marker
dimens
analog
msc
due
featur
acquisit
set
remain
unchang
compar
msc
alon
thu
allow
simultan
visual
cell
type
discrimin
base
express
antibodi
titrat
msc
per
stain
minut
room
temperatur
dark
follow
antibodi
differ
concentr
bd
percpci
bd
apc
bd
incub
cell
wash
pb
analyz
diva
softwar
program
bd
minimum
event
analyz
sampl
evalu
term
percentag
posit
cell
mean
fluoresc
intens
ratio
mfir
calcul
ratio
mfi
posit
cell
popul
mfi
neg
cell
popul
unstain
cell
valu
plot
function
antibodi
quantiti
determin
dilut
best
antibodi
use
follow
step
valid
optim
titer
identifi
lower
quantiti
allow
greatest
discrimin
posit
neg
cell
first
concentr
allow
reach
plateau
instrument
set
acquisit
protocol
manual
calibr
perform
prepar
work
standard
solut
wst
consist
msc
stmsc
mix
cell
seven
tube
prepar
follow
unstain
wst
wst
stain
fitc
bd
wst
stain
pe
bd
wst
stain
wst
stain
percpci
wst
stain
apc
wst
stain
bd
voltag
compens
set
verifi
stain
combin
chosen
antibodi
mix
togeth
percpci
apc
analysi
adjust
made
ensur
fals
stain
occur
dualcolor
quadrant
individu
fluorochrom
set
color
compens
analysi
protocol
defin
precis
histogram
gate
scheme
sampl
valid
step
analyz
protocol
adjust
valid
phase
posit
standard
stmsc
n
combin
neg
standard
differ
ratio
duplic
accord
figur
prepar
n
total
tube
stain
describ
method
paramet
evalu
specif
defin
puriti
abil
detect
posit
marker
msc
condit
defin
percentag
event
impur
abil
detect
neg
marker
b
accuraci
calcul
degre
agreement
expect
measur
percentag
result
accuraci
c
linear
run
dilut
serial
analysi
calcul
r
puriti
impur
precis
estim
repeat
intrarun
intermedi
precis
interrun
cv
less
steril
alway
one
major
critic
test
atmp
releas
particular
time
complet
analysi
may
issu
atmp
product
short
shelflif
regard
paragraph
includ
previou
edit
ph
eur
might
incompat
need
releas
kind
shortliv
atmp
product
thu
make
issu
suitabl
consid
parametr
test
extens
comment
paragraph
recent
edit
ph
eur
aim
facilit
use
steril
analyt
method
includ
altern
approach
reduc
incub
period
time
still
remain
issu
product
must
releas
immedi
complet
manufactur
process
fresh
product
experi
product
cbmsc
cryopreserv
use
result
steril
alway
avail
releas
product
bmmsc
must
releas
fresh
product
requir
altern
approach
valid
test
cbmsc
well
cryopreserv
product
valid
studi
design
aim
verifi
cryopreserv
solut
compon
dmso
normal
salin
human
albumin
could
interfer
detect
microorgan
method
select
direct
inocul
sampl
test
media
describ
ph
eur
chapter
fit
specif
cell
product
membran
filtrat
method
describ
ph
eur
chapter
may
present
difficulti
appli
cell
main
challeng
valid
defin
repres
sampl
final
product
term
volum
condit
fresh
versu
cryopreserv
regard
volum
test
decid
assimil
product
hematopoiet
cell
prepar
ph
eur
prescrib
inocul
total
volum
final
product
volum
greater
ml
consid
number
cellsvolum
cbmsc
batch
vari
manufactur
process
ml
decid
fix
volum
maximum
one
obtain
standard
manufactur
process
ml
reason
valid
purpos
test
ml
final
product
microorgan
strain
regard
condit
final
product
sinc
cbmsc
cryopreserv
must
thaw
clinic
use
steril
test
valid
thaw
retent
sampl
contain
cryopreserv
bag
final
product
routin
qualiti
control
retent
sampl
must
thaw
test
steril
within
three
week
complet
manufactur
process
also
valid
studi
time
schedul
follow
bmmsc
releas
fresh
product
test
sampl
valid
compos
pure
bmmsc
solut
made
normal
salin
human
albumin
volum
chosen
inocul
microbi
strain
ml
total
volum
ml
cbmsc
bmmsc
result
obtain
valid
studi
met
preestablish
accept
criteria
specif
growth
inocul
microorgan
observ
presenc
absenc
cell
product
posit
control
three
valid
run
thu
indic
product
possess
intrins
antibacteri
activ
ii
microbiolog
growth
observ
neg
control
presenc
product
cultur
media
specif
iii
limit
detect
cfu
request
without
product
particular
possibl
detect
microorgan
lowest
quantiti
inocul
cfu
growth
microorgan
observ
seven
day
incub
iv
sampl
analyz
two
differ
oper
two
differ
day
growth
intermedi
precis
recent
revis
ph
eur
chapter
entitl
microbiolog
examin
cellbas
prepar
take
account
characterist
limit
prepar
shelflif
cryopreserv
rang
hour
day
well
sampl
composit
case
cellbas
prepar
inactiv
contamin
microorgan
result
fals
neg
andor
sampl
size
total
volum
batch
could
less
ml
thu
limit
sampl
size
regard
main
chang
previou
version
concern
greater
flexibl
incub
temperatur
chang
list
microorgan
test
yersinia
enterocolitica
replac
micrococcu
luteu
appropri
common
contamin
cellbas
prepar
inform
sensit
achiev
valid
also
includ
sever
author
alreadi
demonstr
exampl
autom
steril
test
capabl
rapidli
detect
lowlevel
contamin
averag
day
within
hour
differ
biopharmaceut
transplant
product
eg
pancreat
islet
also
valid
rapid
steril
test
aim
demonstr
accur
sensit
specif
result
shown
valid
lal
evalu
sensit
specif
test
current
avail
detect
measur
bacteri
endotoxin
defin
pyrogen
induc
fever
advers
reaction
caus
inflammatori
mediat
ph
eur
six
differ
method
determin
endotoxin
pharmaceut
product
describ
paper
present
result
valid
use
kinet
chromogen
test
reaction
time
sampl
compar
control
standard
endotoxin
cse
reaction
time
sampl
defin
onset
time
time
achiev
given
level
optic
densiti
first
aim
valid
design
verifi
suitabl
reagent
specif
sensit
cse
chromogen
method
step
repres
assur
standard
curv
criteria
verifi
three
valu
endotoxin
test
cartridg
euml
report
standard
endotoxin
certif
analysi
includ
central
valu
correspond
amount
endotoxin
load
posit
control
cartridg
last
valu
correspond
sensit
moreov
check
standard
curv
provid
supplier
linear
valu
secondli
valid
product
must
perform
sever
purpos
identifi
possibl
interfer
product
show
chosen
dilut
interfer
elimin
possibl
sourc
interfer
differ
mean
eg
heat
start
valid
studi
specif
endotoxin
limit
el
maximum
valid
dilut
mvd
must
calcul
specif
product
describ
materi
method
calcul
el
mvd
lal
test
atmp
product
good
exampl
difficult
adapt
compendi
method
set
standard
pharmacolog
product
fact
ph
eur
state
new
medicin
product
el
mvd
must
calcul
user
base
administr
rout
pharmacolog
paramet
still
defin
guidelin
explain
ration
follow
defin
valu
atmp
moreov
literatur
author
indic
valu
without
give
justif
calcul
made
determin
other
chose
el
valu
euml
request
food
drug
administr
gener
medic
devic
individu
drug
product
maximum
human
dose
mlkg
condit
tri
respect
much
possibl
spirit
ph
eur
criteria
calcul
el
mvd
product
consider
clinic
use
specif
el
mvd
condit
calcul
follow
k
eukg
request
ph
eur
parenter
administr
maximum
cellular
dose
infus
per
kilogram
singlehour
period
condit
maximum
volum
infus
per
kilogram
cbmsc
maximum
volum
infus
consid
standard
adult
bodi
weight
kg
period
ml
consid
clinic
protocol
report
valid
lal
cbmsc
repres
worst
case
lowest
el
complex
cell
matrix
includ
dmso
calcul
mvd
mvd
euml
euml
preliminari
test
interf
factor
product
test
differ
dilut
order
identifi
suitabl
noninterf
dilut
chosen
sampl
dilut
result
obtain
tabl
satisfi
three
dilut
product
conclud
product
interf
lal
test
valid
decid
use
lowest
dilut
next
phase
order
confirm
chosen
dilut
interfer
test
repeat
three
differ
oper
three
batch
product
experi
session
accept
criteria
met
final
calcul
specif
sensit
test
pss
follow
chosen
dilut
euml
euml
success
perform
lal
valid
cell
product
use
sensit
rapid
quantit
method
encourag
result
sensit
test
much
higher
el
confid
detect
endotoxin
specif
endotoxin
test
product
releas
chosen
accord
el
sensit
test
regard
decis
remov
interf
factor
treat
product
decid
make
manipul
order
test
repres
sampl
releas
final
product
accept
final
dilut
result
consist
support
choic
inde
possibl
case
sampl
interfer
adopt
altern
approach
may
consist
exampl
heat
sampl
modifi
ph
media
case
may
possibl
test
also
lower
dilut
new
frontier
applic
lal
atmp
repres
develop
altern
method
complex
tissueengin
product
combin
product
cell
combin
biomateri
field
altern
method
recent
propos
cellbas
assay
abl
detect
materialbound
microbi
contamin
detect
lal
test
immunofluoresc
stain
assay
evalu
endotoxininduc
express
eselectin
latter
method
could
give
inform
also
regard
local
bacteri
contamin
sourc
step
manufactur
process
tissueengin
product
human
use
valid
atmp
product
carri
risk
adventiti
viru
contamin
airborn
respiratori
virus
introduc
oper
process
test
virus
therefor
essenti
qualiti
control
step
manufactur
biolog
medicin
compendi
guidelin
ich
concern
product
deriv
vitro
cell
cultur
interferon
monoclon
antibodi
recombin
dnaderiv
product
includ
recombin
subunit
vaccin
character
cell
bank
product
gombold
et
al
underlin
limit
ich
vivo
vitro
assay
detect
virus
vaccin
develop
year
ago
suggest
need
new
detect
method
regulatori
monograph
literatur
cover
adventiti
viru
assess
vaccin
specif
guidelin
avail
knowledg
detect
virus
atmp
commerci
kit
moreov
valid
specif
diagnost
use
biolog
materi
blood
nasopharyng
aspir
bronchoalveolar
lavag
condit
valid
three
diagnost
kit
particular
quantit
method
citomegaloviru
cmv
epsteinbarr
viru
ebv
qualit
test
respiratori
virus
cell
product
order
evalu
best
condit
extract
amplif
preliminari
phase
test
three
thaw
batch
cbmsc
differ
cell
dose
cell
result
obtain
intern
posit
control
demonstr
also
lowest
amount
cell
extract
amplif
procedur
success
inhibit
sampl
compon
order
assess
specif
test
bmmsc
dose
cbmsc
inocul
low
high
viral
load
cmv
ebv
enteroviru
hev
adenoviru
adv
shown
figur
respiratori
virus
sampl
band
intern
control
pcrc
whole
process
control
wpc
present
specif
signal
adv
hev
posit
control
also
sampl
spike
viral
load
expect
specif
band
result
neg
control
moreov
demonstr
treatment
proteinas
k
inhibit
rna
extract
also
cmv
ebv
result
provid
realtim
pcr
report
figur
b
c
show
specif
sampl
spike
two
low
high
viral
load
result
obtain
respiratori
virus
cmv
ebv
also
consist
sensit
declar
manufactur
spike
cell
viru
quantiti
near
cutoff
sensit
kit
could
detect
presenc
adv
hev
sampl
data
shown
particular
cmv
ebv
ct
spike
sampl
correl
ct
standard
repres
plasmid
dna
posit
control
virus
absenc
cell
figur
e
also
possibl
calcul
accuraci
error
e
compar
viru
quantiti
batch
cbmsc
cmvand
ebvposit
control
accept
criteria
accuraci
error
satisfi
moreov
precis
criteria
met
sinc
coeffici
variat
within
technic
replic
intraassay
three
differ
batch
cbmsc
cmv
ebv
test
order
guarante
correct
cell
dose
requir
differ
clinic
trial
cell
count
must
accur
manual
count
hemocytomet
commonli
use
method
cell
count
refer
method
describ
ph
eur
chapter
nevertheless
differ
autom
method
avail
market
allow
obtain
operatorindepend
cell
count
gmp
set
becom
extrem
relev
reli
univoc
accur
test
gunetti
et
al
explain
detail
valid
dispos
devic
comparison
burker
chamber
radrizzani
et
al
perform
valid
flow
cytometri
method
laboratori
decid
valid
autom
method
allow
count
global
viabl
total
nucleat
cell
tnc
comparison
burker
chamber
term
accuraci
linear
precis
repeat
intermedi
precis
nucleocount
within
rang
accept
criteria
minimum
maximum
e
autom
total
cell
count
autom
viabl
cell
count
particular
obtain
lowest
discrep
manual
method
autom
method
viabl
cell
count
mean
accuraci
error
viabl
count
versu
total
cell
count
figur
tabl
result
demonstr
oper
well
train
perform
manual
method
accord
written
sop
abl
distinguish
cell
visual
intact
show
sign
death
damag
cell
membran
dilut
experi
figur
indic
autom
manual
method
maintain
good
linear
even
low
cell
concentr
manual
method
inde
appear
less
precis
autom
one
shown
cv
term
repeat
intermedi
precis
notabl
high
cv
found
manual
method
appear
depend
oper
variabl
fact
cv
interoper
rel
low
figur
b
data
demonstr
test
autom
method
accur
precis
ensur
linear
result
obtain
rang
cell
dilut
result
allow
also
defin
optim
cell
concentr
rang
cell
count
cellsml
immunophenotyp
valid
msc
immunophenotyp
character
fundament
identif
cell
product
clinic
applic
lack
specif
distinct
cell
surfac
marker
heterogen
character
studi
led
ten
year
ago
intern
societi
cellular
therapi
isct
publish
minim
criteria
defin
msc
addit
plastic
adher
vitro
differenti
potenti
defin
msc
character
express
lack
express
hematopoiet
endotheli
surfac
marker
hladr
current
criteria
still
use
accept
standard
defin
msc
clinic
applic
flow
cytometri
repres
wide
use
method
immunophenotyp
analysi
also
gmp
set
allow
fast
multiparametr
analysi
cell
suspens
nevertheless
author
alreadi
underlin
assess
analyt
measur
sensit
linear
valid
method
affect
lack
cellular
refer
materi
difficulti
obtain
adequ
control
eg
cell
line
vari
level
given
marker
express
import
prerequisit
valid
process
first
defin
appli
written
procedur
set
instrument
includ
titrat
antibodi
msc
stain
creation
specif
acquisit
protocol
fix
fluoresc
set
compens
data
shown
order
assess
abil
detect
posit
marker
determin
puriti
msc
hematopoiet
marker
detect
impur
chose
spike
msc
differ
concentr
hematopoiet
line
similar
dimensionscatt
msc
simplifi
analysi
decid
take
consider
two
posit
marker
puriti
neg
marker
impur
result
shown
figur
demonstr
puriti
impur
obtain
good
linear
experi
set
r
figur
accuraci
valu
calcul
cv
less
repeat
figur
b
e
less
intermedi
precis
figur
c
accept
criteria
met
valid
allow
us
standard
protocol
msc
puriti
certainti
abl
detect
less
impur
qualiti
control
atmp
much
jeopard
issu
paragraph
pharmacopoeia
dedic
cellular
product
eg
microbiolog
control
atmp
gener
poorli
repres
offici
document
one
demand
challeng
oper
field
person
involv
qualiti
control
adapt
compendi
method
atmp
set
valid
noncompendi
method
first
year
activ
hospitalbas
gmp
facil
first
approv
itali
signific
breakthrough
find
way
toward
effici
ration
valid
approach
ongo
futur
clinic
applic
summar
critic
valid
method
defin
cellular
safeti
ident
puriti
earli
phase
clinic
trial
order
give
use
tool
gmp
manufactur
center
accord
specif
gmp
guidelin
atmp
potenc
assay
expect
valid
prior
pivot
clinic
trial
potenc
regard
relev
biolog
cellular
function
could
influenc
mani
variabl
donor
variabl
cellular
popul
heterogen
immunogen
senesc
resist
cryopreserv
may
affect
effect
vivo
moreov
variabl
togeth
uncertain
mechan
action
lack
refer
standard
make
valid
strategi
difficult
develop
group
alreadi
address
import
issu
work
preciou
open
arena
discuss
order
improv
qualiti
profil
atmp
thu
foster
reliabl
effect
innov
therapeut
tool
data
gener
analys
studi
provid
result
discuss
author
declar
conflict
interest
exist
